Erb-b2 receptor tyrosine kinase 2. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Trastuzumab CHEMBL1201585 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Antibody |
✓ Both | 144 |
| Trastuzumab deruxtecan CHEMBL4297844 |
Receptor protein-tyrosine kinase erbB-2 binding agent Binding agent Antibody drug conjugate |
ChEMBL only | 89 |
| Pertuzumab CHEMBL2007641 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Antibody |
✓ Both | 87 |
| Disitamab Vedotin CHEMBL5095273 |
Receptor tyrosine-protein kinase erbB-2 binding agent Binding agent Antibody drug conjugate |
✓ Both | 66 |
| Pyrotinib CHEMBL3647420 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 47 |
| Trastuzumab emtansine CHEMBL1743082 |
Receptor protein-tyrosine kinase erbB-2 binding agent Binding agent Antibody drug conjugate |
ChEMBL only | 31 |
| Tucatinib CHEMBL3989868 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 23 |
| Afatinib CHEMBL1173655 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 16 |
| Zanidatamab CHEMBL4650256 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Antibody |
ChEMBL only | 14 |
| Neratinib CHEMBL180022 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 8 |
| Dacomitinib CHEMBL2105719 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 5 |
| KN026 CHEMBL4594568 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Unknown |
ChEMBL only | 3 |
| Lapatinib CHEMBL554 |
Receptor protein-tyrosine kinase erbB-2 inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Vandetanib CHEMBL24828 |
Epidermal growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| ARX788 CHEMBL4297892 |
Receptor protein-tyrosine kinase erbB-2 binding agent Binding agent Antibody drug conjugate |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Gastric cancer | 13 | Phase 3 |
| Biliary tract cancer | 10 | Phase 3 |
| Colorectal cancer | 10 | Phase 3 |
| Cancer | 9 | Phase 3 |
| Gastroesophageal junction adenocarcinoma | 9 | Phase 3 |
| Breast cancer | 8 | Phase 3 |
| Gastric adenocarcinoma | 6 | Phase 3 |
| Endometrial cancer | 5 | Phase 3 |
| Esophageal adenocarcinoma | 5 | Phase 3 |
| Gallbladder cancer | 5 | Phase 3 |
| Non-small cell lung carcinoma | 5 | Phase 3 |
| Cholangiocarcinoma | 4 | Phase 3 |
| Cervical cancer | 4 | Phase 2 |
| HER2 positive breast carcinoma | 3 | Phase 3 |
| Colon carcinoma | 3 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
